NeuroSense Therapeutics (NRSN) Competitors $1.47 -0.03 (-2.00%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRSN vs. IMAB, STRO, IGMS, ZURA, ELUT, VTGN, UNCY, INCR, TCRX, and MCRBShould you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include I-Mab (IMAB), Sutro Biopharma (STRO), IGM Biosciences (IGMS), Zura Bio (ZURA), Elutia (ELUT), Vistagen Therapeutics (VTGN), Unicycive Therapeutics (UNCY), InterCure (INCR), TScan Therapeutics (TCRX), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry. NeuroSense Therapeutics vs. I-Mab Sutro Biopharma IGM Biosciences Zura Bio Elutia Vistagen Therapeutics Unicycive Therapeutics InterCure TScan Therapeutics Seres Therapeutics NeuroSense Therapeutics (NASDAQ:NRSN) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Which has stronger valuation and earnings, NRSN or IMAB? NeuroSense Therapeutics has higher earnings, but lower revenue than I-Mab. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/A-$11.28M-$0.54-2.72I-Mab$3.27M24.85-$206.44MN/AN/A Does the MarketBeat Community prefer NRSN or IMAB? I-Mab received 58 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 80.00% of users gave NeuroSense Therapeutics an outperform vote while only 65.26% of users gave I-Mab an outperform vote. CompanyUnderperformOutperformNeuroSense TherapeuticsOutperform Votes480.00% Underperform Votes120.00% I-MabOutperform Votes6265.26% Underperform Votes3334.74% Do insiders and institutionals have more ownership in NRSN or IMAB? 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate NRSN or IMAB? NeuroSense Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 852.38%. I-Mab has a consensus price target of $5.50, suggesting a potential upside of 451.10%. Given NeuroSense Therapeutics' higher probable upside, analysts plainly believe NeuroSense Therapeutics is more favorable than I-Mab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00I-Mab 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more risk and volatility, NRSN or IMAB? NeuroSense Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Does the media prefer NRSN or IMAB? In the previous week, I-Mab had 4 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 4 mentions for I-Mab and 0 mentions for NeuroSense Therapeutics. I-Mab's average media sentiment score of 0.77 beat NeuroSense Therapeutics' score of 0.74 indicating that I-Mab is being referred to more favorably in the news media. Company Overall Sentiment NeuroSense Therapeutics Positive I-Mab Positive Is NRSN or IMAB more profitable? Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A -590.79% I-Mab N/A N/A N/A SummaryI-Mab beats NeuroSense Therapeutics on 8 of the 13 factors compared between the two stocks. Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRSN vs. The Competition Export to ExcelMetricNeuroSense TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.09M$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-2.309.0426.7819.69Price / SalesN/A253.23386.97118.34Price / CashN/A65.8538.2534.62Price / Book-10.506.406.744.50Net Income-$11.28M$143.98M$3.23B$248.32M7 Day Performance16.67%1.90%1.49%-0.03%1 Month Performance45.54%4.01%11.47%12.72%1 Year Performance18.55%-3.00%16.57%7.38% NeuroSense Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRSNNeuroSense Therapeutics2.4447 of 5 stars$1.47-2.0%$14.00+852.4%+19.0%$20.09MN/A-2.3010IMABI-Mab3.1938 of 5 stars$0.91+1.2%$5.50+503.8%-46.4%$74.24M$3.27M0.00380News CoverageSTROSutro Biopharma4.395 of 5 stars$0.88-3.7%$6.11+596.2%-81.5%$74.18M$66.43M-0.55240News CoverageAnalyst ForecastIGMSIGM Biosciences4.2751 of 5 stars$1.24+5.1%$5.50+343.5%-86.0%$74.12M$2.68M-0.34190Positive NewsZURAZura Bio2.8601 of 5 stars$1.08-2.7%$14.33+1,227.2%-81.3%$73.85MN/A-1.543News CoverageAnalyst RevisionELUTElutia3.1654 of 5 stars$1.81+5.2%$8.00+342.0%-49.1%$73.73M$23.71M-0.69180Positive NewsVTGNVistagen Therapeutics1.214 of 5 stars$2.55+3.7%N/A-44.5%$73.60M$698,000.00-1.7240UNCYUnicycive Therapeutics3.224 of 5 stars$0.61+1.7%$5.50+807.6%-44.7%$73.10M$680,000.00-0.629News CoveragePositive NewsAnalyst RevisionINCRInterCure0.7232 of 5 stars$1.58+4.3%N/A-52.9%$72.01M$238.85M0.00350Gap DownTCRXTScan Therapeutics3.9372 of 5 stars$1.24flat$7.80+529.0%-85.8%$70.17M$4.42M-1.17100Positive NewsInsider TradeGap UpHigh Trading VolumeMCRBSeres Therapeutics3.4639 of 5 stars$7.98+7.0%$73.67+823.1%-57.7%$69.68M$126.33M-34.69330Positive NewsGap Down Related Companies and Tools Related Companies IMAB Competitors STRO Competitors IGMS Competitors ZURA Competitors ELUT Competitors VTGN Competitors UNCY Competitors INCR Competitors TCRX Competitors MCRB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRSN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NRSN Stock Free NRSN Stock Alerts